Aprea Therapeutics Reports Third-Quarter Revenue of $0.00
Story updates
01:32:13 PM UTC
SquawkNews
Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026APR-1051 Phase 1 clinical trial expanded to nine sites, with immunohistochemistry (IHC) testing for Cyclin E expressi…
01:32:19 PM UTC
SquawkNews
Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation
01:51:46 PM UTC
SquawkNews
Aprea Therapeutics reported no revenue and a net loss of $4.8 million for the third quarter of 2026, compared with $1800 in revenue and a $3 million net loss a year earlier. Diluted loss per share was $0.09, versus $0.47 in the prior-year quarter.Financial HighlightsBusiness HighlightsOriginal SEC…